Respiratory syncytial virus (RSV) is widely recognized as a leading cause of pneumonia, with substantial mortality, in bone marrow transplant recipients. We tested the efficacy of a systemic monoclonal antibody (MAB) preparation possessing a high titer of anti-RSV neutralizing antibody, palivizumab (Synagis) for prophylaxis and therapy of RSV infection in cytoxan (CY) immunosuppressed cotton rats, a model in which the efficacy of a polyclonal anti-RSV product (Respigam) has been demonstrated. Both prophylaxis and therapy with this MAB were highly effective in reducing pulmonary viral replication. However, multiple sequential therapeutic doses of MAB were necessary to control rebound viral replication in continually suppressed animals. Bone Marrow Transplantation (2002) 29, 117-120. DOI: 10.1038/sj/bmt/1703326 Keywords: RSV; BMT; immunotherapy; palivizumab; Synagis; cotton rat Respiratory syncytial virus (RSV) is widely recognized as one of the major causes of pneumonia in immunocompromised cancer patients. 1 The most striking impact of this pathogen to be identified over the last decade has been its propensity to lead to severe pneumonia during the early period post stem cell transplantation, with a high morbidity and mortality.
Respiratory syncytial virus (RSV) is widely recognized as one of the major causes of pneumonia in immunocompromised cancer patients. 1 The most striking impact of this pathogen to be identified over the last decade has been its propensity to lead to severe pneumonia during the early period post stem cell transplantation, with a high morbidity and mortality. [1] [2] [3] A recent case review reported three deaths among seven patients who developed RSV infections in the post-engraftment period, suggesting a continued significant impact of this pathogen. 4 Those authors also reported an association between RSV infection and both primary and secondary graft failure in four patients. The opinions or assertions contained herein are those of the author(s) and are not to be construed as official or reflecting the views of the Department of Defense, the United States Air Force, or the Uniformed Services University.
The cotton rat model has been a useful tool in the study of RSV pathogenesis and therapy for over 30 years. 5 We recently reported a modification of the use of that model where, by prolonged high-dose cytoxan immunosuppression, we replicated the persistent RSV pneumonia seen in stem cell transplant recipients. 6 In that paper, we demonstrated the ability of a human commercial polyclonal high anti-RSV activity IgG preparation (RSVIG or Respigam) to control RSV replication when given either prophylactically or therapeutically. We return to that model to test the use of the next generation of the product, the humanized anti-RSV monoclonal antibody (MAB) palivizumab (Synagis).
Materials and methods

Animals
Weanling inbred cotton rats (Sigmodon hispidus) were obtained from Virion Systems Incorporated. Animals were housed in large polycarbonate cages in small groups, and were provided water and rat chow ad libitum.
Immunosuppression
Animals were treated with intraperitoneal (i.p.) injections of cyclophosphamide (CY) at a dose of 50 mg/kg three times weekly for at least 21 days prior to viral challenge. Immunosuppressive therapy was continued until the end of each experiment. Prior and current use of this regimen has consistently led to the development of marked leukopenia on day 21 (Ͼ80% reduction in absolute neutrophil and lymphocyte counts) compared with control animals. Also, high pulmonary and nasal RSV titers (5-6 logs/g tissue) are present for at least 16 days in continually suppressed animals, while no virus is recovered from either nasal or pulmonary tissue on or after day 8 in control animals. 6 
Virus
The long strain of RSV (group A), propagated in HEp-2 cells, was used as the challenge virus. A single pool, containing 1 × 10 6 plaque-forming units (p.f.u.) per ml, was used for all experiments.
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Virus assay
Animals were killed by carbon dioxide asphyxiation. Lung and nasal tissues (including turbinates) were homogenized in 10 parts (w/v) of Hank's balanced salt solution supplemented with 0.218 m sucrose, 4.4 mm glutamate, 3.8 mm KH 2 HPO 4 and 7.2 mm K 2 HPO 4 (to stabilize virus during freeze-thawing); and supernatants were stored at −70°C until assayed. Virus titer was determined by plaque assay and expressed as p.f.u. per gram tissue. 7 
Monoclonal antibody preparations
Solutions of 10% palivizumab (MAB) (Medimmune, Gaithersburg, MD, USA) were used for all experiments. In most experiments a dose of 15 mg/kg (identical to the recommended human monthly prophylactic dose) was given intramuscularly (i.m.). In one experimental series animals received twice the standard dose (30 mg/kg) therapeutically to see if very large doses could effect proportionally greater reductions in viral replication.
Experimental designs
For RSV infection, cotton rats were lightly anesthetized with methoxyflurane and inoculated via intranasal lavage with 0.1 ml of RSV containing 10 5 p.f.u. To assess the effectiveness of prophylactic palivizumab, CY-suppressed and normal control animals were given an i.m. injection (15 mg/kg) of the MAB preparation 24 hours prior to virus inoculation, and were killed via CO 2 asphyxiation for tissue virus titration 4 days after the infection. The effectiveness of immunotherapy was assessed by treating CY-suppressed and normal control animals with palivizumab intramuscular injections (with doses of either 15 or 30 mg/kg) 3 days after virus inoculation), followed by death 24 hours later for tissue virus titration. Prophylactic and therapeutic experiments were run twice, with results pooled for analysis. In the last experimental series, which was run once, potential rebound of RSV viral replication in CY-suppressed and control groups of animals after single or multiple doses of palivizumab (all at 15 mg/kg), was assessed by serially killing animals on days 4, 8, 12 and 16, post inoculation.
Statistical analysis
All viral titration results were calculated as geometric means ± standard error for each group. Geometric means of neutralizing antibody titers were determined for each group. Comparative results of tissue viral titers were analyzed by the Student's t-test.
Results
Effectiveness of immunoprophylaxis
Matched groups of CY-suppressed and control animals received passive immunoprophylaxis with a single dose of palivizumab. One day later these animals, along with one additional group each of untreated suppressed and control animals not receiving palivizumab, were infected with RSV. On day 4 post infection, animals were killed for measurement of pulmonary virus titers. The experiment was run twice, with a total of approximately 14 animals sampled per group. Figure 1 summarizes the results of two sequential series of these experiments. Pulmonary virus titers in both suppressed and control animals were greatly reduced when compared to those obtained from untreated comparison groups. Nasal titers were obtained during the second experimental series (not shown) and were likewise barely detectable (Ͻ2.1 logs) in both groups after prophylaxis.
Effectiveness of immunotherapy
Matched groups of CY-suppressed and control animals received passive immunotherapy with single doses of palivizumab (15 or 30 mg/kg) 72 h after infection. On day 4 of experimental infection, animals were killed for measurement of pulmonary virus titers. The experiment was run twice for the 15 mg/kg dose, and once for the 30 mg/kg dose, with a total of 10 to 14 animals per group. Pulmonary titers in both suppressed and control animals that received palivizumab were greatly reduced, when compared to those obtained from untreated comparison groups (Figure 1) , slightly more so with the 30 mg/kg dose. Palivizumab appeared to be equally effective in immunosuppressed and control animals. Nasal titers were likewise barely detectable (Ͻ2.4 logs) in both groups after prophylaxis (not shown).
Evaluation of potential rebound of viral replication
Since viral replication continues at a constant high level in pulmonary and nasal tissues for more than 2 weeks in CY-suppressed animals, 6 it is possible that there could be a rebound of viral replication in suppressed animals after single-dose palivizumab therapy. Three groups of 16 CYsuppressed animals received one of the following: 15 mg/kg of palivizumab therapeutically 3 days after infection; four sequential doses of palivizumab (each at 15 mg/kg) on days 3, 7, 11 and 15 post-RSV infection; or no MAB. The multiple-dose regimen was extrapolated from a past experiment with RSVIG, 6 during which rebound occurred in those CY-suppressed animals treated once, but not in those which received multiple IG treatments 4 days apart. Two identical groups of non-suppressed animals received either a single therapeutic dose of palivizumab (15 mg/kg) 72 h post infection, or no therapy. In all groups, one quarter of the animals were killed each on days 4, 8, 12 and 16, for determination of pulmonary tissue virus titers. Figure 2 summarizes the results of these experimental series. Non-suppressed animals which received one dose of palivizumab had no RSV detectable on or after day 4, while those which received no MAB were found to have approximately 4.7 logs of RSV per gram lung tissue detectable on day 4, and none thereafter. Untreated CY-suppressed animals had persistent high levels of virus (5 to 6 logs of RSV per gram) recovered from pulmonary tissues consistently through the 16 day period. In contrast, CY-suppressed animals that received palivizumab therapy once demonstrated a greater than 2 log reduction of virus compared to untreated suppressed animals on day 4, but rebounded almost to the level of untreated animals 4 days later, with subsequent persistent intermediate levels of replication. Multiple doses of palivizumab at 4-day intervals were able to greatly reduce rebound of viral replication in continually suppressed animals. 
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Discussion
Using our immunosuppressed cotton rat model that replicates the severe and prolonged lower respiratory RSV infection seen early post stem cell transplant, we have demonstrated that palivizumab is highly effective in reducing pulmonary and nasal viral replication in suppressed animals, either as prophylaxis or therapy. Although 'rebound' of pulmonary viral replication was again observed in animals receiving continued immunosuppression, this was easily controlled by modest repeated doses of palivizumab. Throughout this experimental series, standard doses of palivizumab led to reductions of RSV achieved previously by only large doses of RSVIG, indicating that palivizumab is more efficient. In fact, in our past work with RSVIG, we used a total of 2 g per kg over 15 days to prevent rebound of RSV replication in persistently suppressed animals, 6 while in the current series of experiments we achieved greater suppression with a total dose of only 60 mg per kg of palivizumab. Recent attempts to treat stem cell transplant patients with severe RSV pneumonia have relied on regimens which combine large doses of RSVIG and aerosolized ribavirin. 8, 9 Replacement of RSVIG with palivizumab could allow the delivery of large amounts of anti-RSV antibody activity, possibly through multiple repeat doses, without the significant fluid/protein challenge posed by large amounts of RSVIG. These studies suggest a role for palivizumab immunoprophylaxis and therapy in stem cell transplant patients.
